RG
NGNE icon

Redmile Group’s Neurogene NGNE Stock Holding History

Redmile Group’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.4M Sell
1,412,199
-47,400
-3% -$1.3M 2.98% 10
2026
Q1 		$29.4M Hold
1,459,599
– – 1.95% 11
2025
Q4 		$30.1M Buy
1,459,599
+160,577
+12% +$4M 2.21% 11
2025
Q3 		$22.5M Buy
1,299,022
+22,346
+2% +$449K 2.19% 14
2025
Q2 		$19.1M Sell
1,276,676
-31,387
-2% -$493K 2.03% 15
2025
Q1 		$15.3M Sell
1,308,063
-11,700
-0.9% -$203K 1.45% 19
2024
Q4 		$30.2M Buy
1,319,763
+355,416
+37% +$13.2M 2.1% 18
2024
Q3 		$40.5M Sell
964,347
-49,316
-5% -$1.91M 2.38% 17
2024
Q2 		$36.9M Buy
1,013,663
+78,411
+8% +$2.77M 2.23% 19
2024
Q1 		$47.6M Sell
935,252
-11,645
-1% -$389K 1.75% 19
2023
Q4 		$18.4M Buy
946,897
+801,286
+550% +$11.5M 0.66% 40
2023
Q3 		$2.3M Hold
145,611
– – 0.11% 58
2023
Q2 		$2.42M Buy
145,611
+53,231
+58% +$873K 0.09% 66
2023
Q1 		$1.29M Sell
92,380
-148
-0.2% -$1.74K 0.06% 70
2022
Q4 		$942K Sell
92,528
-79,319
-46% -$819K 0.04% 66
2022
Q3 		$2.2M Hold
171,847
– – 0.09% 63
2022
Q2 		$3.54M Sell
171,847
-1,425
-0.8% -$34.8K 0.14% 62
2022
Q1 		$6.51M Sell
173,272
-1,270
-0.7% -$74.1K 0.2% 57
2021
Q4 		$16.8M Sell
174,542
-820
-0.5% -$99.9K 0.38% 48
2021
Q3 		$25.4M Sell
175,362
-20,600
-11% -$3.15M 0.44% 49
2021
Q2 		$36.2M Sell
195,962
-9,916
-5% -$2.19M 0.54% 49
2021
Q1 		$50.7M Sell
205,878
-715
-0.3% -$183K 0.71% 42
2020
Q4 		$58.3M Sell
206,593
-2,041
-1% -$499K 0.71% 43
2020
Q3 		$50.1M Buy
208,634
+6,573
+3% +$1.59M 0.92% 38
2020
Q2 		$67.1M Hold
202,061
– – 1.24% 24
2020
Q1 		$46M Buy
202,061
+106,019
+110% +$21.8M 1.29% 27
2019
Q4 		$23.7M Buy
+96,042
New +$9.57M 0.57% 46
2015
Q4 		– Sell
-25,715
Closed -$7.24M – 63
2015
Q3 		$7.24M Buy
+25,715
New +$5.92M 0.55% 37

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Redmile Group's NGNE Position: Q2 2026 in Review

Redmile Group reduced its Neurogene (NGNE) stake by 3.2% in Q2 2026, selling an estimated $1.3M and leaving 1,412,199 shares worth $44.4M. The position accounts for 2.98% of the portfolio, ranked #10.

Redmile Group first reported a position in NGNE in Q3 2015 and has held it in 28 quarters since. The position peaked at $67.1M in Q2 2020. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • Redmile Group held 1,412,199 shares of Neurogene worth $44.4M as of Q2 2026.
  • Redmile Group sold 47,400 Neurogene shares in Q2 2026, an estimated $1.3M.
  • Neurogene made up 2.98% of Redmile Group's portfolio in Q2 2026, its #10 holding.
  • Redmile Group first reported a position in Neurogene in Q3 2015 and has held it in 28 quarters since.
  • Redmile Group's Neurogene position peaked at $67.1M in Q2 2020.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Redmile Group's 13F filing for Q2 2026, filed 14 Aug 2026.